Caxton Corporation’s ALX Oncology ALXO Stock Holding History

Caxton Corporation’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$42K	Buy	+20,946	New	+$39.9K	1.04%	7

Other funds holding ALXO

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Caxton Corporation's ALXO Position: Q1 2026 in Review

Caxton Corporation opened a new position in ALX Oncology (ALXO) in Q1 2026: 20,946 shares worth $42K. The stake represents 1.04% of the portfolio and ranks #7 among its holdings.

69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

Caxton Corporation held 20,946 shares of ALX Oncology worth $42K as of Q1 2026.
ALX Oncology was a new Caxton Corporation position in Q1 2026.
ALX Oncology made up 1.04% of Caxton Corporation's portfolio in Q1 2026, its #7 holding.
69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on Caxton Corporation's 13F filing for Q1 2026, filed 14 May 2026.